Ethnicity based differences in statin use and hypercholesterolemia control among patients with premature coronary artery disease-results of I-PAD study.
Karimi R, Zarepur E, Khosravi A, Mohammadifard N, Nouhi F, Alikhasi H, Nasirian S, Sadeghi M, Roohafza H, Moezi Bady SA, Parisa Janjani, Solati K, Lotfizadeh M, Ghaffari S, Javanmardi E, Gholipour M, Mostafa Dehghani, Cheraghi M, Assareh A, Haybar H, Namayandeh SM, Reza Madadi, Kojuri J, Mansourian M, Sarrafzadegan N.
Karimi R, et al.
Int J Cardiol Cardiovasc Risk Prev. 2023 Jan 14;16:200168. doi: 10.1016/j.ijcrp.2023.200168. eCollection 2023 Mar.
Int J Cardiol Cardiovasc Risk Prev. 2023.
PMID: 36874039
Free PMC article.
After adjustment to all confounders (full model), the odds of controlling LDL were lower for Gilak in Lovastatin, Rosuvastatin, and Simvastatin by 0.64 (0.47, 0.75); 0.61 (0.43, 0.73); 0.63 (0.46, 0.74) respectively and higher for Arab in Lovastatin, Rosuvastatin, and Simv …
After adjustment to all confounders (full model), the odds of controlling LDL were lower for Gilak in Lovastatin, Rosuvastatin, and S …